An Act to Reduce Cost and Increase Access to Disease Prevention by Expanding the Universal Childhood Immunization Program to Include Adults
LD 93 expands Maine’s Universal Childhood Immunization Program beyond children to include adults, and renames the program in practice by changing its operative scope from “children from birth until 19 years of age” to “individuals in the State.” The bill directs the Maine Vaccine Board and the Department of Health and Human Services to administer a uniform set of vaccines for adults as well as children, using recommendations from the CDC Advisory Committee on Immunization Practices and other clinical and cost-benefit considerations. It also updates program definitions, board operations, reporting requirements, and the fund structure to reflect the broader population covered.
The bill creates a framework for assessing insurers and other assessed entities to finance adult vaccine coverage, including quarterly assessments beginning July 1, 2025, reconciliation of actual costs, interim assessments for new vaccines, and an adjustment factor (AAF) to account for differences among carriers. It also adds an administrative allowance, preserves the existing trust-fund structure, and specifies that the fund cannot be used to subsidize other programs. The appropriations section anticipates implementation costs and savings, including two public health educator positions and reduced MaineCare vaccine costs from purchasing adult vaccines at CDC discounted prices, with the act taking effect July 1, 2026.
The bill amends 22 MRSA §1066, the statute governing the Universal Childhood Immunization Program, to extend vaccine access and financing mechanisms to adults residing in Maine. It also makes conforming changes to related reporting and funding provisions in 22 MRSA §1963, and adds new statutory definitions and assessment rules that affect the Maine Vaccine Board, the Department of Health and Human Services, insurers, and other assessed entities. In practical terms, it shifts the program from a child-focused immunization system to a broader statewide adult-and-child vaccine access program, while preserving the existing board-administered trust fund and assessment-based financing model.
The voting history suggests the bill was controversial but ultimately advanced with majority support. Recorded votes show close margins on key motions, including enactment and acceptance of the majority ought-to-pass-as-amended report, indicating substantial support but also significant opposition. The bill’s stated goals of reducing costs and increasing access to disease prevention likely appealed to supporters focused on public health and affordability, while opponents appear to have had concerns significant enough to produce narrow votes and an unsuccessful attempt to table the measure.
The main points of contention appear to be the expansion of a childhood immunization program to adults and the financing mechanism used to support that expansion. Likely areas of dispute include whether insurers and other assessed entities should bear the cost, how assessments are calculated and adjusted, and whether the state should commit to adult vaccine coverage through this existing program structure. The addition of the AAF, the quarterly assessment schedule, and the possibility of interim assessments for new vaccines suggest technical concerns about fairness, cost allocation, and administrative complexity. The close votes indicate that while many legislators supported the public health rationale, others were not persuaded or had reservations about cost, scope, or implementation.